Phase 2 Emapalumab Trial for Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NIH registered a Phase 2 clinical trial (NCT07538336) on ClinicalTrials.gov evaluating emapalumab as a treatment for interferon gamma-high acute lung allograft dysfunction in lung transplant recipients. The randomized, placebo-controlled study will assess whether emapalumab can restore lung function to baseline levels within 90 days. Participants have been diagnosed with ALAD, a condition with no currently approved therapeutic options.

Affected parties include transplant centers, pulmonologists, and clinical investigators interested in alloimmune lung injury research. Sponsors and clinical research organizations may use this registration to identify trial sites or benchmark against existing interventional approaches for post-transplant complications. The trial represents standard pharmaceutical development activity and does not impose compliance obligations on non-participating entities.